The Janus kinase 2 (JAK2)-driven myeloproliferative neoplasms (MPNs) are associated with clonal myelopoiesis. elevated risk of death due to thrombotic complications. and transformation to acute myeloid leukemia (AML). JAK2 inhibitors improve the quality of life for MPN patients. https://halohealthcarers.shop/product-category/health-care/